Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Hegenbart

Showing results (1-10 of 237) with videos related to

Pageof 24
Sort By:
Blood|January 7, 2017
Flow in a fibril-forming diseaseStefan Schönland, Ute Hegenbart
Deutsche Medizinische Wochenschrift (1946)|October 9, 2024
[Amyloidosis]Ute Hegenbart, Kiavasch M N Farid, Stefan Schönland
Transplantation|December 30, 2022
Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal SignificanceBen Sprangers, Ute Hegenbart, Jack F M Wetzels
Innere Medizin (Heidelberg, Germany)|August 4, 2023
[Light chain amyloidosis]Ute Hegenbart, Fabian Aus dem Siepen, Stefan Schönland
Acta Haematologica|June 23, 2020
Prognosis and Staging of AL AmyloidosisTobias Dittrich, Christoph Kimmich, Ute Hegenbart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Reply to R. Warsame et alTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Annals of the Rheumatic Diseases|April 23, 2024
bDMARD can prevent the progression of AA amyloidosis to end-stage renal diseasePeter Kvacskay, Ute Hegenbart, Hanns-Martin Lorenz, et al.
Die Ophthalmologie|August 4, 2022
[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect]Victor A Augustin, Louise Blöck, Ute Hegenbart, et al.
Virchows Archiv : an International Journal of Pathology|February 26, 2016
Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patientsSophie Freudenthaler, Ute Hegenbart, Stefan Schönland, et al.
Blood|November 29, 2017
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survivalTomas Pika, Ute Hegenbart, Pavla Flodrova, et al.
Pageof 24

Showing results (1-10 of 237) with videos related to

Sort By:
Pageof 24
Blood|January 7, 2017
Flow in a fibril-forming diseaseStefan Schönland, Ute Hegenbart
Deutsche Medizinische Wochenschrift (1946)|October 9, 2024
[Amyloidosis]Ute Hegenbart, Kiavasch M N Farid, Stefan Schönland
Transplantation|December 30, 2022
Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal SignificanceBen Sprangers, Ute Hegenbart, Jack F M Wetzels
Innere Medizin (Heidelberg, Germany)|August 4, 2023
[Light chain amyloidosis]Ute Hegenbart, Fabian Aus dem Siepen, Stefan Schönland
Acta Haematologica|June 23, 2020
Prognosis and Staging of AL AmyloidosisTobias Dittrich, Christoph Kimmich, Ute Hegenbart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Reply to R. Warsame et alTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Annals of the Rheumatic Diseases|April 23, 2024
bDMARD can prevent the progression of AA amyloidosis to end-stage renal diseasePeter Kvacskay, Ute Hegenbart, Hanns-Martin Lorenz, et al.
Die Ophthalmologie|August 4, 2022
[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect]Victor A Augustin, Louise Blöck, Ute Hegenbart, et al.
Virchows Archiv : an International Journal of Pathology|February 26, 2016
Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patientsSophie Freudenthaler, Ute Hegenbart, Stefan Schönland, et al.
Blood|November 29, 2017
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survivalTomas Pika, Ute Hegenbart, Pavla Flodrova, et al.
Pageof 24